Join Joseph Dennis at the Laboratory Robotics Interest Group - LRIG Bay Area Fall Event for his presentation "Empowering Discovery with an AI-Driven Automated Platform” and a discussion of the critical role of automation in Iambic’s drug discovery platform. #AI, #drugdiscovery, #machinelearning
Iambic Therapeutics
Biotechnology Research
San Diego, CA 7,996 followers
Charting new paths to superior medicines
About us
Iambic Therapeutics is disrupting the therapeutics landscape with its unique AI-driven drug-discovery platform. Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters with strong track records of success in delivering clinically validated therapeutics. The Iambic platform has been demonstrated to deliver high-quality, differentiated therapeutics to clinic with unprecedented speed and across multiple target classes and mechanisms of action. The Iambic team is advancing an internal pipeline of clinical assets to address urgent unmet patient needs. Learn more about the Iambic team, platform, and pipeline at iambic.ai.
- Website
-
http://www.iambic.ai
External link for Iambic Therapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- San Diego, CA
- Type
- Privately Held
- Founded
- 2019
- Specialties
- machine learning, artificial intelligence, drug discovery, catalysis, materials, sustainability, chemistry, biochemistry, pharmaceuticals, polymers, quantum mechanics, molecular simulation, batteries, and energy
Locations
-
Primary
San Diego, CA, US
-
5627 Oberlin Dr
Suite 120
San Diego, California 92121, US
Employees at Iambic Therapeutics
-
Sophie Coon
Innovative Product Leader: Driving Results in Technical Environments with Cross-Disciplinary Expertise | Artist at Sophie Coon Studios
-
William Barnes
Executive Director | Head of GPCR Biology at Iambic Therapeutics
-
Jose Alberto Quiroz Ramos
Executive Director at Iambic Therapeutics
-
John Lamoureux
Senior IT Leader | Business Relationship Management | Infrastructure & Operations | Security | Life Sciences | Biotechnology | Pharma
Updates
-
Iambic Therapeutics reposted this
Italian Tech Week was so fun! It was a real honour to be on the stage with Ileana Pirozzi, Fred (Federico) Parietti and Raviv Pryluk. But also wonderful to be in the City of #Torino and to meet so many people focused on improving the world through the creation of technology. #italiantechweek #biotech #AI for #drugdiscovery
-
We are deeply honored to be named to this year’s Endpoints 11 list of most promising private biotech companies. This recognition by Endpoints News is a tribute to the entire Iambic Therapeutics team and their tremendous work in bringing highly-differentiated, AI-discovered drug candidates to clinic. Thank you to John Carroll, Andrew Dunn and Drew Armstrong for this award and their appreciation for the transformational advances AI and machine learning bring to the discovery of potential breakthrough medicines for patients. #EndpointsNews #AI #drugdiscovery #machinelearning See today’s announcement here: https://lnkd.in/gMuC8s67
-
We are pleased to announce a new strategic partnership with CNS therapeutics leader Lundbeck and to use our state-of-the-art, AI-driven drug discovery platform to accelerate research that can unlock novel development candidates for neurological disease. See today’s announcement here: https://lnkd.in/g59Y9smS #AI #machinelearning #Drugdiscovery #CNS
-
Looking forward to a fascinating panel discussion #italiantechweek on The bio-industrial revolution: Robots, Quantum and AI, which will be moderated by https://lnkd.in/gSU57pRS of https://lnkd.in/g-CKhg9G. Panelists include our CTO Fred Manby along with PhaseV CEO https://lnkd.in/gXtgGHbx and Multiply Labs CEO https://lnkd.in/g-ArDjrU. The program takes place on September 25th at 15:02 local time on the Fucine Stage at the OGR Torino Exhibition Hall in Turin, Italy. We hope to see you there. #AI #machinelearning #drugdiscovery #ITW24
-
Our globetrotting CTO Fred Manby lands in Barcelona on September 19th to present and participate in a fireside chat on The future of AI in shaping Drug Discovery at the 24th Drug Discovery Innovation Programme. Dr. Manby will discuss our AI/ML and automated experimentation platform and how it is transforming the pace at which highly-differentiated drug candidates advance from discovery to the clinic. #drugdiscovery #AI #machinelearning
-
Join Iambic’s CTO Fred Manby at the 1st Quantum Mechanics in Pharma meeting in London next week for a discussion on the role of quantum mechanics in driving the future of drug discovery. This will include a discussion of Iambic’s OrbNet machine learning model that provides the accuracy of quantum chemistry a thousand times faster. #drugdiscovery #quantum #AI #machinelearning
-
Mary’s track record as a physician, her drug development and regulatory experience, and her distinguished expertise in oncology and related therapeutic areas will enrich our board as we as we advance potential first- and best-in-class cancer therapies. https://lnkd.in/gQyVPPgP
-
Our CTO Fred Manby will join other technology leaders at the 15th Annual Drug Discovery Innovation Forum in Berlin, where he will discuss Iambic’s drug discovery platform and how integrated machine learning and lab automation enables Iambic to rapidly identify and advance novel therapeutic candidates. https://lnkd.in/d8EFpTuh #DDIF2024 #AI #ML #DrugDiscovery
-
Honored to have our CEO Thomas Miller recognized as a Leader of Influence in Life Science for 2024 by the San Diego Business Journal! San Diego is a tremendous hub for biotech innovation and talent. At Iambic we look forward to continuing our growth in the community as we broaden our clinical pipeline of AI-discovered therapeutics. https://lnkd.in/e2uRbM45 #AI, #machinelearning, #drugdiscovery